RLAY Relay Therapeutics Forecast, Technical & Fundamental Analysis
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients... Show more
RLAY is expected to report earnings to fall 3.95% to -39 cents per share on August 06
Q2'26
Est.
$-0.39
Q1'26
Missed
by $0.05
Q4'25
Beat
by $0.09
Q3'25
Missed
by $0.01
Q2'25
Beat
by $0.08
The last earnings report on May 05 showed earnings per share of -40 cents, missing the estimate of -36 cents. With 1.02M shares outstanding, the current market capitalization sits at 4.02B.
A.I. Advisor
published General Information
General Information
a clinical-stage precision medicines company, which focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets
A.I.dvisor indicates that over the last year, RLAY has been loosely correlated with KURA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RLAY jumps, then KURA could also see price increases.
RLAY in -1.09% downward trend, declining for three consecutive days on July 23, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where RLAY declined for three days, in of 319 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for RLAY moved out of overbought territory on July 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 54 cases where RLAY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on July 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RLAY as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for RLAY turned negative on July 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .
RLAY broke above its upper Bollinger Band on June 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RLAY advanced for three days, in of 264 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 217 cases where RLAY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RLAY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.258) is normal, around the industry mean (20.216). P/E Ratio (0.000) is within average values for comparable stocks, (37.938). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.504). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (303.030) is also within normal values, averaging (394.724).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
